Weight loss · Maplewood, MN
Weight loss and obesity studies in Maplewood, MN
5 recruiting studies have a site in Maplewood.
5 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
Pfizer
- Location
- Maplewood, MN + 2 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Maplewood, MN + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Maplewood, MN + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Maplewood, MN + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Maplewood, MN + 117 other US sites
- Eligibility basics
- Ages 18–99
Who these studies look for
Most of these studies set a BMI range and may exclude people taking certain weight-loss medicines or who have had bariatric surgery. Some require a weight-related condition such as type 2 diabetes or high blood pressure.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.